Vir Encouraging Data in Ongoing Trials for Dual Masked T-Cell Engagers in Solid Tumors, mCRPC

 – Compelling early clinical response signals for VIR-5818 and VIR-5500 in heavily pretreated patients with various solid tumors

○ VIR-5818: In patients receiving doses ≥400 µg/kg, tumor shrinkage observed in 50% (10/20) of participants with various HER2-expressing cancers; confirmed partial responses in 33% (2/6) of participants with HER2-positive CRC

○ VIR-5500: PSA declines in 100% (12/12) and PSA50 response confirmed in 58% (7/12) of mCRPC patients with first step dose ≥120 µg/kg

– Promising safety profile with MTD not yet reached for VIR-5818 or VIR-5500 and no dose-limiting cytokine release syndrome (CRS) observed; no CRS greater than grade 2 reported

– Initial clinical data demonstrate PRO-XTEN™ masking technology may lead to minimal systemic unmasking and unlocks expanded therapeutic index

– Investor conference call January 8, 2025, at 5:00 a.m. PT / 8:00 a.m. ET, available on https://investors.vir.bio

https://www.businesswire.com/news/home/20250108263221/en